World-first peanut allergy trial seeking participants

Australian hospitals are taking part in world-first human trials of a new peanut allergy treatment. (AP PHOTO)

World-first human trials of a new treatment for peanut allergy likened to a "heat-seeking missile" will soon start, with hopes it could eventually stop reactions to shellfish.

About three in every 100 Australian children have a peanut allergy and current treatments focus on reducing symptoms rather than stopping it at the source.

However, the new medication targets antibodies in the body's own immune system that cause reactions and aims to alter them and stop the response from happening.

From September, phase one trials will be conducted in Australia by US-based biotechnology company IgGenix with Fiona Stanley Hospital, St Vincent’s Hospital, The Royal Melbourne Hospital and Monash Health.

It's the first time such a treatment has been used to treat a food allergy, Fiona Stanley consultant immunologist Michael O'Sullivan told AAP.

He said scientists and doctors have been talking about a treatment like this for two decades and it's exciting Australian hospitals were involved from such an early stage.

"This is a really significant step forward in providing potential future treatment, which will actually take away that risk of having allergic reactions and anaphylaxis from accidentally eating peanuts," Dr O'Sullivan said.

It would likely be a good option for teenagers and adults who still have a peanut allergy, he said, with one dose of the medication potentially offering protection for several weeks or months.

The new medication acts like a "heat-seeking missile", IgGenix chief executive Jessica Grossman said.

"(Allergic) people make these bad fighter antibodies against peanut," she said.

IgGenix CEO Jessica Grossman.
IgGenix CEO Jessica Grossman says a new peanut allergy treatment acts like a "heat-seeking missile".

"We start with those antibodies but we transform them, we re-engineer them into neutral, blocking antibodies."

About 24 healthy people aged 15 to 55 in Melbourne, Sydney and Perth are needed for phase-one trials.

Participants will be injected with the medication and closely monitored for several months as doctors assess safety, dosage, any side effects and measure levels of protection in the blood.

"At 30 days, we'll give them a very small control dose of peanut to see if the drug is safe in the face of a peanut challenge and also if there's any signal of effectiveness," Dr Grossman said.

If all goes well she hopes all trials would wrap up within five years, with IgGenix also developing a similar treatment for shellfish allergies.

Immunologists involved in a trial of a new peanut allergy treatment.
Immunologists have met in Melbourne ahead of a trial of a new peanut allergy treatment.

Prominent immunologists met in Melbourne this week to finalise trial details and Dr O'Sullivan said testing the medication here could ensure Australians are among the first in the world to access it if approved.

"We're really keen to make sure that we can keep working together across all of the different hospitals in Australia to bring these sorts of treatments to Australian patients from very early in the process, rather than waiting years down the track to finally get access to them," he said.

Dr O'Sullivan said it may also offer hope for patients with many other types of allergies.

"If it turns out to be effective for peanuts, the science behind this and the discovery of these specific antibodies from patients with peanut allergy can also be replicated for people who have got allergies to other nuts or to shellfish, milk or egg," he said.

License this article

What is AAPNews?

For the first time, Australian Associated Press is delivering news straight to the consumer.

No ads. No spin. News straight-up.

Not only do you get to enjoy high-quality news delivered straight to your desktop or device, you do so in the knowledge you are supporting media diversity in Australia.

AAP Is Australia’s only independent newswire service, free from political and commercial influence, producing fact-based public interest journalism across a range of topics including politics, courts, sport, finance and entertainment.

What is AAPNews?
The Morning Wire

Wake up to AAPNews’ morning news bulletin delivered straight to your inbox or mobile device, bringing you up to speed with all that has happened overnight at home and abroad, as well as setting you up what the day has in store.

AAPNews Morning Wire
AAPNews Breaking News
Breaking News

Be the first to know when major breaking news happens.


Notifications will be sent to your device whenever a big story breaks, ensuring you are never in the dark when the talking points happen.

Focused Content

Enjoy the best of AAP’s specialised Topics in Focus. AAP has reporters dedicated to bringing you hard news and feature content across a range of specialised topics including Environment, Agriculture, Future Economies, Arts and Refugee Issues.

AAPNews Focussed Content
Subscription Plans

Choose the plan that best fits your needs. AAPNews offers two basic subscriptions, all billed monthly.

Once you sign up, you will have seven days to test out the service before being billed.

AAPNews Full Access Plan
Full Access
AU$10
  • Enjoy all that AAPNews has to offer
  • Access to breaking news notifications and bulletins
  • Includes access to all AAPNews’ specialised topics
Join Now
AAPNews Student Access Plan
Student Access
AU$5
  • Gain access via a verified student email account
  • Enjoy all the benefits of the ‘Full Access’ plan at a reduced rate
  • Subscription renews each month
Join Now
AAPNews Annual Access Plan
Annual Access
AU$99
  • All the benefits of the 'Full Access' subscription at a discounted rate
  • Subscription automatically renews after 12 months
Join Now

AAPNews also offers enterprise deals for businesses so you can provide an AAPNews account for your team, organisation or customers. Click here to contact AAP to sign-up your business today.

SEVEN DAYS FREE
Download the app
Download AAPNews on the App StoreDownload AAPNews on the Google Play Store